Thelansis’s “Hepatocellular Carcinoma (HCC) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Hepatocellular carcinoma is the most common form of primary liver cancer and typically develops in the setting of underlying chronic liver disease, most often related to viral hepatitis, heavy alcohol use, or the growing contribution of metabolic dysfunction-associated fatty liver conditions, so addressing the disease increasingly requires treating the liver damage that gave rise to it alongside the tumor itself. Treatment is guided heavily by disease stage and underlying liver function rather than tumor characteristics alone, with early disease often managed through surgical removal, ablation, or transplantation, while more advanced or inoperable disease increasingly relies on systemic therapy. That systemic landscape has changed substantially in recent years, moving away from single targeted agents toward immunotherapy-based combinations as the preferred first-line approach, with several distinct combination regimens now available. Locoregional treatments such as tumor-directed embolization also continue to play a role, particularly for intermediate-stage disease, and are increasingly paired with systemic therapy rather than used alone.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Hepatocellular Carcinoma (HCC) – Epidemiology Insights and Disease Burden Report – 2020 To 2040 report
Our team will get in touch with you shortly about the Hepatocellular Carcinoma (HCC) – Epidemiology Insights and Disease Burden Report – 2020 To 2040 report.